Marker’s unique manufacturing process selectively expands a range of naturally occurring, often extremely rare tumor-specific T cells present in patients’ blood that are able to recognize unique epitopes of up to five different tumor-associated antigens. The result is a robust mixture of T cells that can target a broad repertoire of cancer cells within a single tumor, with the benefit of bypassing expensive, time-consuming, and complex genetic modification. Additionally, the innovative G-Rex® cell culture platform further reduces the cost and complexity of manufacturing by providing a simple and scalable solution to individualized cell culture.

A typical patient dose consists of approximately 4,000 unique anti-tumor T cell types, which when reintroduced into the patient, are able to kill heterogeneous tumor targets more effectively than single-antigen specific approaches. This reduces the likelihood of tumor “escape” and increases the durability of a patient’s response to therapy.